Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study.
Imène DabbakMathieu P RoderoFlorence A AeschlimannFrançois Jérôme AuthierChristine BodemerPierre Quartier Dit MaireVincent BondetJean-Luc CharuelDarragh DuffyCyril GitiauxBrigitte Bader-MeunierPublished in: Rheumatology (Oxford, England) (2022)
Conventional first-line treatment with MTX was not efficient in a large subset of JDM patients, especially in patients with MSA-positive forms, and in patients with severe JDM. Larger, multicentre cohorts are required to confirm these data and to identify new predictive biomarkers of MTX response, in order to treat patients with JDM as early as possible with appropriate targeted drugs.
Keyphrases
- ejection fraction
- newly diagnosed
- clinical trial
- prognostic factors
- high dose
- electronic health record
- cancer therapy
- interstitial lung disease
- study protocol
- early onset
- rheumatoid arthritis
- big data
- patient reported outcomes
- randomized controlled trial
- systemic lupus erythematosus
- artificial intelligence
- peritoneal dialysis